MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL

被引：0

作者：

Yau, Christina ^{[1
]}

Wolf, Denise M. ^{[1
]}

Sanil, Ashish ^{[2
]}

Chien, Jo ^{[1
]}

Wallace, Anne ^{[3
]}

Boughey, Judy ^{[4
]}

Yee, Doug ^{[5
]}

Tripathy, Debu ^{[6
]}

DeMichele, Angela ^{[7
]}

Nanda, Rita ^{[8
]}

Chiu, Steven ^{[9
]}

Isaacs, Claudine ^{[10
]}

Albain, Kathy ^{[11
]}

Kaplan, Hank ^{[12
]}

Moulder, Stacey ^{[13
]}

Viscusi, Rebecca ^{[14
]}

Northfelt, Donald ^{[4
]}

Edmiston, Kirsten ^{[15
]}

Elias, Anthony ^{[16
]}

Styblo, Toncred ^{[17
]}

Haley, Barbara ^{[18
]}

Brown-Swigart, Lamorna ^{[1
]}

Flynn, Susan ^{[1
]}

Hirst, Gillian L. ^{[1
]}

Buxton, Meredith ^{[1
]}

Hylton, Nola ^{[1
]}

Paoloni, Melissa ^{[19
]}

Symmans, W. Fraser ^{[13
]}

Esserman, Laura ^{[1
]}

Berry, Don ^{[2
]}

Liu, Minetta C. ^{[4
]}

Park, John W. ^{[1
]}

van 't Veer, Laura ^{[1
]}

机构：

[1] Univ Calif, Davis, CA USA

[2] Berry Consultants LLC, Austin, TX USA

[3] Univ Calif San Diego, San Diego, CA 92103 USA

[4] Mayo Clin, Rochester, MN USA

[5] Univ Minnesota, Minneapolis, MN 55455 USA

[6] Univ So Calif, Los Angeles, CA 90089 USA

[7] Univ Penn, Philadelphia, PA 19104 USA

[8] Univ Chicago, Chicago, IL 60637 USA

[9] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[10] Georgetown Univ, Washington, DC 20057 USA

[11] Loyola Univ Med Ctr, Maywood, IL 60153 USA

[12] Swedish Canc Inst, Seattle, WA USA

[13] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[14] Univ Arizona, Tucson, AZ 85721 USA

[15] Inova Hlth Syst, Ames, IA USA

[16] Univ Colorado, Boulder, CO 80309 USA

[17] Emory Univ, Atlanta, GA 30322 USA

[18] Univ Texas, Houston, TX USA

[19] Quantum Leap Healthcare, Los Angeles, CA USA

来源：

CANCER RESEARCH | 2015年 / 75卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3-06-29

引用

页数：2

共 50 条

[1] MammaPrint High1/High2 risk class as a biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL
Wolf, Denise M.
Yau, Christina
Sanil, Ashish
Chien, Jo
Wallace, Anne
DeMichele, Angela
Kaplan, Hank
Yee, Doug
Isaacs, Claudine
Albain, Kathy
Viscuzi, Rebecca
Boughey, Judy
Moulder, Stacey
Chui, Steven
Khan, Qamar
Styblo, Toncred
Edmiston, Kirsten
Northfelt, Donald
Elias, Anthony
Haley, Barbara
Tripathy, Debu
Brown-Swigart, Lamorna
Flynn, Susan
Hirst, Gillian
Buxton, Meredith
Hylton, Nola
Paoloni, Melissa
Symmans, Fraser
Esserman, Laura
Berry, Don
Rugo, Hope
Olopade, Olufunmilayo I.
van 't Veer, Laura
[J]. CANCER RESEARCH, 2015, 75
[2] MammaPrint High1/High2 risk class as a pre-specified biomarker of response to nine different targeted agents plus standard neoadjuvant therapy for ∼1000 breast cancer patients in the I-SPY 2 TRIAL
van't Veer, L. J.
Wolf, D.
Yau, C.
Glas, A.
Brown-Swigart, L.
Asare, S.
Hirst, G.
Hylton, N.
Symmans, F.
Berry, D.
Demichele, A.
Yee, D.
Esserman, L.
[J]. EUROPEAN JOURNAL OF CANCER, 2018, 103 : E15 - E15
[3] Gene and pathway differences between MammaPrint High1/High2 risk classes: results from the I-SPY 2 TRIAL in breast cancer
Wolf, Denise M.
Yau, Christina
Brown-Swigart, Lamorna
Hirst, Gillian
Buxton, Meredith
Paoloni, Melissa
Olopade, Olufunmilayo
De Michele, Angela
Symmans, Fraser
Rugo, Hope
Berry, Don
Esserman, Laura
van't Veer, Laura
[J]. CANCER RESEARCH, 2016, 76
[4] DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer
Wolf, D. M.
Yau, C.
Sanil, A.
Glas, A.
Petricoin, C.
Wulfkuhle, J.
Brown-Swigart, L.
Hirst, G.
Buxton, M.
DeMichele, A.
Hylton, N.
Symmans, F.
Yee, D.
Paoloni, M.
Esserman, L.
Berry, D.
Rugo, H.
Olapade, O.
van't Veer, L.
[J]. CANCER RESEARCH, 2017, 77
[5] Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL
Park, John W.
Liu, Minetta C.
Yee, Douglas
DeMichele, Angela
van't Veer, Laura
Hylton, Nola
Symmans, Fraser
Buxton, Meredith B.
Chien, A. Jo
Wallace, Amy
Melisko, Michelle
Schwab, Richard
Boughey, Judy
Tripathy, Debashish
Kaplan, Hank
Nanda, Rita
Chui, Stephen
Albain, Kathy S.
Moulder, Stacy
Elias, Anthony
Lang, Julie E.
Edminston, Kirsten
Northfelt, Donald
Euhus, David
Khan, Qamar
Lyandres, Julia
Davis, Sarah E.
Yau, Christina
Sanil, Ashish
Esserman, Laura J.
Berry, Donald A.
[J]. CANCER RESEARCH, 2014, 74 (19)
[6] The evaluation of trebananib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL
Albain, K. S.
Leyland-Jones, B.
Symmans, F.
Paoloni, M.
van't Veer, L.
DeMichele, A.
Buxton, M.
Hylton, N.
Yee, D.
Clennell, J. Lyandres
Yau, C.
Sanil, A.
Berry, D.
Esserman, L.
[J]. CANCER RESEARCH, 2016, 76
[7] Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2
Nanda, Rita
Liu, Minetta C.
Yau, Christina
Asare, Smita
Hylton, Nola
Van't Veer, Laura
Perlmutter, Jane
Wallace, Anne M.
Chien, Amy Jo
Forero-Torres, Andres
Ellis, Erin
Han, Heather
Clark, Amy Sanders
Albain, Kathy S.
Boughey, Judy Caroline
Elias, Anthony D.
Berry, Donald A.
Yee, Douglas
DeMichele, Angela
Esserman, Laura
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[8] Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial
Glas, A.
Peeters, J.
Yau, C.
Wolf, D. M.
Sanil, A.
Li, Y.
Severson, T.
Linn, S.
Buxton, M.
DeMichele, A.
Hylton, N.
Symmans, F.
Yee, D.
Paoloni, M.
Esserman, L.
Berry, D.
Rugo, H.
Olopade, O.
van 't Veer, L. J.
[J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 173 - 173
[9] Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL
Rugo, H. S.
Olopade, O.
DeMichele, A.
van't Veer, L.
Buxton, M.
Hylton, N.
Yee, D.
Chien, A. J.
Wallace, A.
Lyandres, J.
Davis, S.
Sanil, A.
Berry, D.
Esserman, L.
[J]. CANCER RESEARCH, 2013, 73
[10] Biomarkers predicting response to durvalumab combined with olaparib in the neoadjuvant I-SPY 2 TRIAL for high-risk breast cancer
Wolf, Denise M.
Yau, Christina
Brown-Swigart, Lamorna
O'Grady, Nick
Hirst, Gillian
Sit, Laura
Asare, Smita
Berry, Don
Esserman, Laura
Han, Hyo
Pusztai, Lajos
van 't Veer, Laura
[J]. CANCER RESEARCH, 2021, 81 (04)

← 1 2 3 4 5 →